N‐glycosylation of PD‐1 promotes binding of camrelizumab

PD‐1 is a highly glycosylated inhibitory receptor expressed mainly on T cells. Targeting of PD‐1 with monoclonal antibodies (MAbs) to block the interaction with its ligand PD‐L1 has been successful for the treatment of multiple tumors. However, polymorphisms at N‐glycosylation sites of PD‐1 exist in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EMBO Rep
Hauptverfasser: Liu, Kefang, Tan, Shuguang, Jin, Wanjun, Guan, Jiawei, Wang, Qingling, Sun, Huan, Qi, Jianxun, Yan, Jinghua, Chai, Yan, Wang, Zhongfu, Deng, Chuxia, Gao, George F
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2020
Schlagworte:
Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7726772/
https://ncbi.nlm.nih.gov/pubmed/33063473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embr.202051444
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge